62 related articles for article (PubMed ID: 25319884)
1. Analysis of receptor tyrosine kinase (RTK) phosphorylation by immunoblotting.
McDermott M; O'Donovan N
Methods Mol Biol; 2015; 1233():3-14. PubMed ID: 25319884
[TBL] [Abstract][Full Text] [Related]
2. Analysis of changes in phosphorylation of receptor tyrosine kinases: antibody arrays.
Rani S; O'Driscoll L
Methods Mol Biol; 2015; 1233():15-23. PubMed ID: 25319885
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
4. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
5. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.
Harbinski F; Craig VJ; Sanghavi S; Jeffery D; Liu L; Sheppard KA; Wagner S; Stamm C; Buness A; Chatenay-Rivauday C; Yao Y; He F; Lu CX; Guagnano V; Metz T; Finan PM; Hofmann F; Sellers WR; Porter JA; Myer VE; Graus-Porta D; Wilson CJ; Buckler A; Tiedt R
Cancer Discov; 2012 Oct; 2(10):948-59. PubMed ID: 22874768
[TBL] [Abstract][Full Text] [Related]
6. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.
Paulson AK; Linklater ES; Berghuis BD; App CA; Oostendorp LD; Paulson JE; Pettinga JE; Melnik MK; Vande Woude GF; Graveel CR
Mol Cancer Res; 2013 Sep; 11(9):1112-21. PubMed ID: 23825050
[TBL] [Abstract][Full Text] [Related]
7. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
Yang C; Liu Y; Lemmon MA; Kazanietz MG
Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
[TBL] [Abstract][Full Text] [Related]
8. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
9. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.
Organ SL; Tong J; Taylor P; St-Germain JR; Navab R; Moran MF; Tsao MS
J Proteome Res; 2011 Jul; 10(7):3200-11. PubMed ID: 21609022
[TBL] [Abstract][Full Text] [Related]
10. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
11. α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
Michikoshi H; Nakamura T; Sakai K; Suzuki Y; Adachi E; Matsugo S; Matsumoto K
Cancer Lett; 2013 Jul; 335(2):472-8. PubMed ID: 23507559
[TBL] [Abstract][Full Text] [Related]
12. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
Stern YE; Al-Ghabkari A; Monast A; Fiset B; Aboualizadeh F; Yao Z; Stagljar I; Walsh LA; Duhamel S; Park M
Cell Mol Life Sci; 2022 Mar; 79(3):178. PubMed ID: 35249128
[TBL] [Abstract][Full Text] [Related]
13. Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.
Weber H; Müller D; Müller M; Ortiz A; Birkle M; Umber S; Ketterer C; Siedentopf O; Feger D; Totzke F; Kubbutat M; Schaechtele C; Ballmer-Hofer K; Ehlert JE; Graeser R
J Biomol Screen; 2014 Dec; 19(10):1350-61. PubMed ID: 25260782
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
15. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Schaefer G; Shao L; Totpal K; Akita RW
Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
[TBL] [Abstract][Full Text] [Related]
17. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
19. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
20. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.
Frazier NM; Brand T; Gordan JD; Grandis J; Jura N
Oncogene; 2019 Mar; 38(11):1936-1950. PubMed ID: 30390071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
